Fish oil supplementation during pregnancy, anthropometrics, and metabolic health at age ten: A randomized clinical trial
- PMID: 38569788
- DOI: 10.1016/j.ajcnut.2023.12.015
Fish oil supplementation during pregnancy, anthropometrics, and metabolic health at age ten: A randomized clinical trial
Erratum in
-
Corrigendum to 'Fish-oil supplementation during pregnancy, anthropometrics, and metabolic health at age 10; a randomized clinical trial' [Am J Clin Nutr 119(4) (2024) 960-968].Am J Clin Nutr. 2024 Jun;119(6):1536. doi: 10.1016/j.ajcnut.2024.04.011. Epub 2024 Apr 24. Am J Clin Nutr. 2024. PMID: 38664140 No abstract available.
Abstract
Background: We previously reported that children of mothers who received fish oil supplementation during pregnancy had higher body mass index [BMI (in kg/m2)] at 6 y of age as well as a concomitant increase in fat-, muscle, and bone mass, but no difference in fat percentage.
Objectives: Here, we report follow-up at age 10 y including assessment of metabolic health.
Methods: This is a follow-up analysis of a randomized clinical trial conducted among 736 pregnant females and their offspring participating in the Copenhagen Prospective Studies on Asthma in Childhood mother-child cohort. The intervention was 2.4 g n-3 (ω-3) Long-Chain PolyUnsaturated Fatty Acid (n-3 LCPUFA) or control daily from pregnancy week 24 until 1 wk after birth. Outcomes were anthropometric measurements, body composition from Bioelectrical Impedance Analysis, blood pressure, concentrations of triglycerides, cholesterol, glucose, and C-peptide from fasting blood samples, and a metabolic syndrome score was calculated. Anthropometric measurements and body composition were prespecified secondary endpoints of the n-3 LCPUFA trial, and others were exploratory.
Results: Children in the n-3 LCPUFA group had a higher mean BMI at age 10 year compared to the control group: 17.4 (SD: 2.44) compared with 16.9 (2.28); P = 0.020 and a higher odds ratio of having overweight (odds ratio: 1.53; 95% CI: 1.01, 2.33; P = 0.047). This corresponded to differences in body composition in terms of increased lean mass (0.49 kg; 95% CI: -0.20, 1.14; P = 0.17), fat mass (0.49 kg; 95% CI: -0.03, 1.01; P = 0.06), and fat percent (0.74%; 95% CI: -0.01, 1.49; P = 0.053) compared to the control group. Children in the n-3 LCPUFA group had a higher metabolic syndrome score compared to the control (mean difference: 0.19; 95% CI: -0.02, 0.39; P = 0.053).
Conclusions: In this randomized clinical trial, children of mothers receiving n-3 LCPUFA supplementation had increased BMI at age 10 y, increased risk of being overweight, and a tendency of increased fat percentage and higher metabolic syndrome score. These findings suggest potential adverse health effects from n-3 LCPUFA supplementation during pregnancy and need to be replicated in future independent studies. This trial was registered at clinicaltrials.gov as NCT00798226.
Keywords: RCT; childhood; fish oil; growth; obesity.
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
Comment in
-
A follow-up from a randomized controlled trial suggests that fish oil in pregnancy may increase the risk of obesity and metabolic syndrome in the offspring-a reason for concern?Am J Clin Nutr. 2024 Apr;119(4):863-864. doi: 10.1016/j.ajcnut.2024.01.015. Epub 2024 Feb 22. Am J Clin Nutr. 2024. PMID: 38569781 No abstract available.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical